I\u27m Goin\u27 South : Fox Trot Song

https://digitalcommons.library.umaine.edu/mmb-vp/1783/thumbnail.jp

Bebe : Fox Trot Song

https://digitalcommons.library.umaine.edu/mmb-vp/2840/thumbnail.jp

Dark Chocolate (70% Cacao) Modulates Gamma Wave Frequencies in Vigorously Active Individuals

Background: Visualization and the demand to increase cognitive function to improve performance is an area of growing interest in athletes and physically active individuals. Gamma (25-45 Hz) waves, the fastest of the brainwave frequencies, are optimal for cognitive function. Objective: Determine if savoring and ingestion of dark chocolate (70% cacao) can modulate gamma wave frequencies between visualization at a state of rest and a state of exercise performance in vigorously active individuals. Participants/setting: The study recruited 10 vigorously active individuals from Loma Linda University. Participants’ mean age was 23.7± 2.2 years. Vigorous activity was defined by the Centers for Disease Control and America College of Sports Medicine. Intervention: Participant visualization of rest and exercise were assessed by EEG Power Spectral Density (PSD) during three 60-second trials: without cacao (1.4 g of 70% cacao) consumption, savoring cacao, and after fully ingesting cacao. EEG wave band activity was recorded from 9 cerebral cortical scalp locations. Statistical analyses performed: Z-scores, using a reference baseline at visualization or rest without cacao were utilized. Results: During visualization of rest, there was a significant increase of 541.5% in gamma wave frequency when comparing no cacao to savoring cacao (p=\u3c.001). During exercise visualization, there was a significant increase of 207.5% in gamma wave frequency when comparing no cacao to savoring cacao (p=\u3c.001). Z-score PSD of overall gamma wave frequencies were lowest in the absence of cacao during rest and exercise respectively (.32, .75). During visualization of rest, there was a significant decrease of 58.0% in gamma waves when comparing savoring cacao to fully ingesting cacao (p=\u3c.001). Conclusions: We suggest that EEG gamma waves are heightened during savoring and ingestion of 1.4 g of cacao, when visualization of rest and exercise take place

Good-Morning, Good-Evening, Good-Night

Picture on left side of a man kissing a woman\u27s hand and two butterflies on each side of the picturehttps://scholarsjunction.msstate.edu/cht-sheet-music/5380/thumbnail.jp

Learning from Monte Carlo Rollouts with Opponent Models for Playing Tron

This paper describes a novel reinforcement learning system for learning to play the game of Tron. The system combines Q-learning, multi-layer perceptrons, vision grids, opponent modelling, and Monte Carlo rollouts in a novel way. By learning an opponent model, Monte Carlo rollouts can be effectively applied to generate state trajectories for all possible actions from which improved action estimates can be computed. This allows to extend experience replay by making it possible to update the state-action values of all actions in a given game state simultaneously. The results show that the use of experience replay that updates the Q-values of all actions simultaneously strongly outperforms the conventional experience replay that only updates the Q-value of the performed action. The results also show that using short or long rollout horizons during training lead to similar good performances against two fixed opponents

Darling, Not Without You

Portrait of Eddie Duchin; Iillustration of man and womenhttps://scholarsjunction.msstate.edu/cht-sheet-music/12734/thumbnail.jp

Walking For Health: A Community Education and Physical Activity Initiative

Background/Introduction: Vermont was ranked the nation’s healthiest state, according to 2007 America’s Health Rankings. However obesity, currently the second most common cause of death among VT adults, is becoming so common it may replace cigarette smoking as the number one risk factor for death. In fact obesity affects 21% of adults in VT, most commonly low income adults. Obesity is a risk factor for high cholesterol, high blood pressure, heart diseases, and diabetes. Diet quality and physical activity are important factors in preventing obesity. 42% of Vermont adults are below the recommended level of physical activity. Greater knowledge about nutrition correlates with improved diet quality and greater physical activity. A successful educational strategy on physical activity and nutrition promotes group activities and adapts for cultural relevance.https://scholarworks.uvm.edu/comphp_gallery/1013/thumbnail.jp

FIGO consensus guidelines on placenta accreta spectrum disorders : Prenatal diagnosis and screening

Peer reviewe

Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial

Background Negative symptoms of schizophrenia represent deficiencies in emotional responsiveness, motivation, socialisation, speech and movement. When persistent, they are held to account for much of the poor functional outcomes associated with schizophrenia. There are currently no approved pharmacological treatments. While the available evidence suggests that a combination of antipsychotic and antidepressant medication may be effective in treating negative symptoms, it is too limited to allow any firm conclusions. Objective To establish the clinical effectiveness and cost-effectiveness of augmentation of antipsychotic medication with the antidepressant citalopram for the management of negative symptoms in schizophrenia. Design A multicentre, double-blind, individually randomised, placebo-controlled trial with 12-month follow-up Setting Adult psychiatric services, treating people with schizophrenia. Participants Inpatients or outpatients with schizophrenia, on continuing, stable antipsychotic medication, with persistent negative symptoms at a criterion level of severity. Interventions Eligible participants were randomised 1 : 1 to treatment with either placebo (one capsule) or 20 mg of citalopram per day for 48 weeks, with the clinical option at 4 weeks to increase the daily dosage to 40 mg of citalopram or two placebo capsules for the remainder of the study. Main Outcome Measures The primary outcomes were quality of life measured at 12 and 48 weeks assessed using the Heinrich’s Quality of Life Scale, and negative symptoms at 12 weeks measured on the negative symptom subscale of the Positive and Negative Syndrome Scale. Results No therapeutic benefit in terms of improvement in quality of life or negative symptoms was detected for citalopram over 12 weeks or at 48 weeks, but secondary analysis suggested modest improvement in the negative symptom domain, avolition/amotivation, at 12 weeks (mean difference –1.3, 95% confidence interval–2.5 to–0.09). There were no statistically significant differences between the two treatment arms over 48-week follow-up in either the health economics outcomes or costs, and no differences in the frequency or severity of adverse effects, including corrected QT interval prolongation. Limitations The trial under-recruited, partly because cardiac safety concerns about citalopram were raised, with the 62 participants recruited falling well short of the target recruitment of 358. Although this was the largest sample randomised to citalopram in a randomised controlled trial of antidepressant augmentation for negative symptoms of schizophrenia and had the longest follow-up, the power of statistical analysis to detect significant differences between the active and placebo groups was limited. Conclusion Although adjunctive citalopram did not improve negative symptoms overall, there was evidence of some positive effect on avolition/amotivation, recognised as a critical barrier to psychosocial rehabilitation and achieving better social and community functional outcomes. Comprehensive assessment of side-effect burden did not identify any serious safety or tolerability issues. The addition of citalopram as a long-term prescribing strategy for the treatment of negative symptoms may merit further investigation in larger studies. Future Work Further studies of the viability of adjunctive antidepressant treatment for negative symptoms in schizophrenia should include appropriate safety monitoring and use rating scales that allow for evaluation of avolition/amotivation as a discrete negative symptom domain. Overcoming the barriers to recruiting an adequate sample size will remain a challenge.</p

Analysis of coding variants in the betacellulin gene in type 2 diabetes and insulin secretion in African American subjects

BACKGROUND: Betacellulin is a member of the epidermal growth factor family, expressed at the highest levels predominantly in the pancreas and thought to be involved in islet neogenesis and regeneration. Nonsynonymous coding variants were reported to be associated with type 2 diabetes in African American subjects. We tested the hypotheses that these previously identified variants were associated with type 2 diabetes in African Americans ascertained in Arkansas and that they altered insulin secretion in glucose tolerant African American subjects. METHODS: We typed three variants, exon1 Cys7Gly (C7G), exon 2 Leu44Phe (L44F), and exon 4 Leu124Met (L124M), in 188 control subjects and 364 subjects with type 2 diabetes. We tested for altered insulin secretion in 107 subjects who had undergone intravenous glucose tolerance tests to assess insulin sensitivity and insulin secretion. RESULTS: No variant was associated with type 2 diabetes, and no variant altered insulin secretion or insulin sensitivity. However, an effect on lipids was observed for all 3 variants, and variant L124M was associated with obesity measures. CONCLUSION: We were unable to confirm a role for nonsynonymous variants of betacellulin in the propensity to type 2 diabetes or to impaired insulin secretion